Retargeting of human T cells to tumor-associated MUC1: The evolution of a chimeric antigen receptor

Journal of Immunology

Volumn 180, Issue 7, 2008, Pages 4901-4909

  Wilkie, Scott ^a   Picco, Gianfranco ^a   Foster, Julie ^d   Davies, David M ^a   Julien, Sylvain ^a   Cooper, Lucienne ^a   Arif, Sefina ^b   Mather, Stephen J ^d   Taylor Papadimitriou, Joyce ^d   Burchell, Joy M ^a   Maher, John ^a,b,c  

^a Department of Surgery   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAR ANTIGEN; CD134 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; GAMMA INTERFERON; HOX PROTEIN; IMMUNOGLOBULIN D; INTERLEUKIN 17; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HMFG2; MUCIN 1; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; CA 15-3 ANTIGEN; HOMEODOMAIN PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; GENE INSERTION; GENETIC ENGINEERING; GLYCOSYLATION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; SIGNAL TRANSDUCTION; T LYMPHOCYTE; CARBOHYDRATE METABOLISM; CELL CULTURE; CYTOTOXICITY; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASM; PROTEIN BINDING; PROTEIN ENGINEERING;

CA-15-3 ANTIGEN; CARBOHYDRATE METABOLISM; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOGLOBULIN D; NEOPLASMS; PROTEIN BINDING; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN; T-LYMPHOCYTES;

EID: 44449162630     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.7.4901     Document Type: Article

References (44)

1. Hanisch, F. G., G. Uhlenbruck, J. Peter-Katalinic, H. Egge, J. Dabrowski, and U. Dabrowski. 1989. Structures of neutral O-linked polylactosaminoglycans on human skim milk mucins: a novel type of linearly extended poly-N-acetyllac- tosamine backbones with Gal β(1-4)GlcNAc β(1-6) repeating units. J. Biol. Chem. 264: 872-883.
2. Gaemers, I. C., H. L. Vos, H. H. Volders, S. W. van der Valk, and J. Hilkens. 2001. A stat-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cells. J. Biol. Chem. 276:6191-6199.
3. Girling, A., J. Bartkova, J. Burchell, S. Gendler, C. Gillett, and J. Taylor-Papadimitriou. 1989. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int. J. Cancer 43: 1072-1076.
4. van Dam, P. A., D. G. Lowe, J. V. Watson, T. W. Jobling, T. Chard, and J. H. Shepherd. 1991. Multi-parameter flow cytometric quantitation of the expression of the tumor-associated antigen SM3 in normal and neoplastic ovarian tissues: a comparison with HMFG1 and HMFG2. Cancer 68: 169 -177.
5. Hilkens, J., F. Buijs, J. Hilgers, P. Hageman, J. Calafat, A. Sonnenberg, and M. van der Valk. 1984. Monoclonal antibodies against human milk: fat globule membranes detecting differentiation antigens of the mammary gland and its tumours. Int. J. Cancer 34: 197-206.
6. Burchell, J., R. Poulsom, A. Hanby, C. Whitehouse, L. Cooper, H. Clausen, D. Miles, and J. Taylor-Papadimitriou. 1999. An α2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiology 9: 1307-1311.
7. Sewell, R., M. Backstrom, M. Dalziel, S. Gschmeissner, H. Karlsson, T. Noll, J. Gatgens, H. Clausen, G. C. Hansson, J. Burchell, and J. Taylor-Papadimitriou. 2006. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J. Biol. Chem. 281: 3586 -3594.
8. Brockhausen, I., J. M. Yang, J. Burchell, C. Whitehouse, and J. Taylor- Papadimitriou. 1995. Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur. J. Biochem. 233: 607-617.
9. Lloyd, K. O., J. Burchell, V. Kudryashov, B. W. Yin, and J. Taylor- Papadimitriou. 1996. Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines: demonstration of simpler and fewer glycan chains in tumor cells. J. Biol. Chem. 271: 33325-33334.
10. Burchell, J., S. Gendler, J. Taylor-Papadimitriou, A. Girling, A. Lewis, R. Millis, and D. Lamport. 1987. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 47: 5476 -5482.
11. Tarp, M. A., A. L. Sorensen, U. Mandel, H. Paulsen, J. Burchell, J. Taylor-Papadimitriou, and H. Clausen. 2007. Identification of a novel cancer- specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Gly- cobiology 17: 197-209.
12. Hayes, D. F., H. Sekine, T. Ohno, M. Abe, K. Keefe, and D. W. Kufe. 1985. Use of murine monoclonal antibody for detection of circulating DF3 plasma antigen levels in breast cancer patients. J. Clin. Invest. 75: 1671-1678.
13. Ragupathi, G., N. X. Liu, C. Musselli, S. Powell, K. Lloyd, and P. O. Livingston. 2005. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J. Immunol. 174: 5706 -5712.
14. Agrawal, B., M. J. Krantz, M. A. Reddish, and B. M. Longenecker. 1998. Cancer- associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Vat. Med. 4: 43-49.
15. van de Wiel-van Kemenade, E., M. J. Ligtenberg, A. J. de Boer, F. Buijs, H. L. Vos, C. J. Melief, J. Hilkens, and C. G. Figdor. 1993. Episialin (MUC1) inhibits cytotoxic lymphocyte-target-cell interaction. J. Immunol. 151: 767-776.
16. Sadelain, M., I. Riviere, and R. Brentjens. 2003. Targeting tumours with genetically enhanced T lymphocytes. Vat. Rev. Cancer 3: 35-45.
17. Lamers, C. H., S. Sleijfer, A. G. Vulto, W. H. Kruit, M. Kliffen, R. Debets, J. W. Gratama, G. Stoter, and E. Oosterwijk. 2006. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24: e20-e2.
18. Kershaw, M. H., J. A. Westwood, L. L. Parker, G. Wang, Z. Eshhar, S. A. Mavroukakis, D. E. White, J. R. Wunderlich, S. Canevari, L. Rogers-Freezer, et al. 2006. A phase I study on adoptive immunotherapy using gene-modified T-cells for ovarian cancer. Clin. Cancer Res. 12: 6106-6115.
19. Maher, J., R. J. Brentjens, G. Gunset, I. Riviere, and M. Sadelain. 2002. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Vat. Biotechnol. 20: 70 -75.
20. Haynes, N. M., J. A. Trapani, M. W. Teng, J. T. Jackson, L. Cerruti, S. M. Jane, M. H. Kershaw, M. J. Smyth, and P. K. Darcy. 2002. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100: 3155-3163.
21. Pule, M. A., K. C. Straathof, G. Dotti, H. E. Heslop, C. M. Rooney, and M. K. Brenner. 2005. A chimeric T-cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T-cells. Mol. Ther. 12:933-941.
22. Stephan, M. T., V. Ponomarev, R. J. Brentjens, A. H. Chang, K. V. Dobrenkov, G. Heller, and M. Sadelain. 2007. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Vat. Med. 13:1440 -1449.
23. Paul, S., D. Snary, J. Hoebeke, D. Allen, J. M. Balloul, N. Bizouarne, K. Dott, M. Geist, J. Hilgers, M. P. Kieny, et al. 2000. Targeted macrophage cytotoxicity using a nonreplicative live vector expressing a tumor-specific single-chain variable region fragment. Hum. Gene Ther. 11: 1417-1428.
24. Loset, G. A., K. H. Roux, P. Zhu, T. E. Michaelsen, and I. Sandlie. 2004. Differential segmental flexibility and reach dictate the antigen binding mode of chi- meric IgD and IgM: implications for the function of the B cell receptor. J. Immunol. 172: 2925-2934.
25. Link, T., M. Backstrom, R. Graham, R. Essers, K. Zorner, J. Gatgens, J. Burchell, J. Taylor- Papadimitriou, G. C. Hansson, and T. Noll. 2004. Bioprocess development for the production of a recombinant MUC1 fusion protein expressed by CHO-K1 cells in protein-free medium. J. Biotechnol. 110: 51-62.
26. Backstrom, M., T. Link, F. J. Olson, H. Karlsson, R. Graham, G. Picco, J. Burch- ell, J. Taylor-Papadimitriou, T. Noll, and G. C. Hansson. 2003. Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells. Biochem. J. 376: 677-686.
27. Kingsley, D. M., K. F. Kozarsky, L. Hobbie, and M. Krieger. 1986. Reversible defects in O-linked glycosylation and LDL receptor expression in a UDP-Gal/ UDP-GalNAc 4-epimerase deficient mutant. Cell 44: 749-759.
28. Engelmann, K., C. L. Kinlough, S. Muller, H. Razawi, S. E. Baldus, R. P. Hughey, and F. G. Hanisch. 2005. Transmembrane and secreted MUC1 probes show trafficking-dependent changes in O-glycan core profiles. Glycobi-ology 15: 1111-1124.
29. Burchell, J., and J. Taylor-Papadimitriou. 1993. Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product. Epithelial Cell Biol. 2: 155-162.
30. Guest, R. D., R. E. Hawkins, N. Kirillova, E. J. Cheadle, J. Arnold, A. O'Neill, J. Irlam, K. A. Chester, J. T. Kemshead, D. M. Shaw, et al. 2005. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J. Immunother. 28: 203-211.
31. Sun, Z., A. Almogren, P. B. Furtado, B. Chowdhury, M. A. Kerr, and S. J. Perkins. 2005. Semi-extended solution structure of human myeloma immu- noglobulin D determined by constrained x-ray scattering. J. Mol. Biol. 353:155-173.
32. Watts, T. H. 2005. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23: 23-68.
33. Komiyama, Y., S. Nakae, T. Matsuki, A. Nambu, H. Ishigame, S. Kakuta, K. Sudo, and Y. Iwakura. 2006. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177: 566 -573.
34. Hu, J., X. Yuan, M. L. Belladonna, J. M. Ong, S. Wachsmann-Hogiu, D. L. Farkas, K. L. Black, and J. S. Yu. 2006. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res. 66: 8887-8896.
35. Langowski, J. L., R. A. Kastelein, and M. Oft. 2007. Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol. 28: 207-212.
36. Maraveyas, A., D. Snook, V. Hird, C. Kosmas, C. F. Meares, H. E. Lambert, and A. A. Epenetos. 1994. Pharmacokinetics and toxicity of an yttrium-90-CITC- DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. Cancer 73: 1067-1075.
37. Epenetos, A. A., V. Hird, H. Lambert, P. Mason, and C. Coulter. 2000. Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int. J. Gynecol. Cancer 10: 44-46.
38. Vera, J., B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti. 2006. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant-cells. Blood 108: 3890-3897.
39. Brentjens, R. J., E. Santos, Y. Nikhamin, R. Yeh, M. Matsushita, K. La Perle, A. Quintas-Cardama, S. M. Larson, and M. Sadelain. 2007. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 13: 5426-5435.
40. Alajez, N. M., J. Schmielau, M. D. Alter, M. Cascio, and O. J. Finn. 2005. Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution. Blood 105: 4583-4589.
41. Hacein-Bey-Abina, S., C. Von Kalle, M. Schmidt, M. P. McCormack, N. Wulffraat, P. Leboulch, A. Lim, C. S. Osborne, R. Pawliuk, E. Morillon, et al. 2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
42. Ott, M. G., M. Schmidt, K. Schwarzwaelder, S. Stein, U. Siler, U. Koehl, H. Glimm, K. Kuhlcke, A. Schilz, H. Kunkel, et al. 2006. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12: 401-409.
43. Recchia, A., C. Bonini, Z. Magnani, F. Urbinati, D. Sartori, S. Muraro, E. Tagliafico, A. Bondanza, M. T. Stanghellini, M. Bernardi, et al. 2006. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc. Natl. Acad. Sci. USA 103:1457-1462.
44. Muul, L. M., L. M. Tuschong, S. L. Soenen, G. J. Jagadeesh, W. J. Ramsey, Z. Long, C. S. Carter, E. K. Garabedian, M. Alleyne, M. Brown, et al. 2003. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 101: 2563-2569.